Dr. Delle Curti Clelia Teresa

Doctor

Contacts

Mail: clelia.dellecurti@istitutotumori.mi.it
Tel: 0223902480

Specialty / Department

Radiation oncology

My educational journey began with the achievement of a degree in Medicine and Surgery with honors in 2013 from the “Luigi Vanvitelli” University in Naples. Subsequently, I specialized in Radiation Oncology with top marks at the University of Milano Bicocca, and I obtained a professional collaboration contract at the IRCCS National Cancer Institute Foundation in Milan for a research project concerning the quality of MRI-guided brachytherapy treatment in cervical cancer.

Since the first year of my specialization, I have dedicated myself to the treatment of neoplastic diseases in the gynecological area, actively participating in the multidisciplinary team. I focus on treatments using advanced radiation therapy techniques, stereotactic radiation therapy, and brachytherapy.

Regarding brachytherapy, I specialize in performing gynecological endocavitary and interstitial brachytherapy treatments, guided by CT and MRI images, as well as interstitial prostate brachytherapy treatments.

Starting in 2024, I also began working on contact and interstitial brachytherapy for eyelid tumors. I am a co-author of several scientific publications and have participated in various national and international studies as a sub-investigator. I am a member of scientific societies such as AIRO, ESTRO, and MITO.

Intraluminal Brachytherapy in Unresectable Extrahepatic Biliary Duct Cancer. Anticancer Res . 2020 Jun;40(6):3417-3421. doi: 10.21873/anticanres.14326.
Patterns of failure after adjuvant "sandwich" chemo-radio-chemotherapy in locally advanced (stage III-IVA) endometrial cancer Multicenter Study J Cancer Res Clin Oncol . 2021 Mar;147(3):813-820. doi: 10.1007/s00432-020-03339-y. Epub 2020 Jul 30
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer. Multicenter Study Gynecol Oncol . 2024 May:184:16-23. doi: 10.1016/j.ygyno.2024.01.023.

-Phase III randomized clinical trial, double-blind, aimed at comparing chemoradiotherapy + Pembrolizumab (MK-3475) vs chemoradiotherapy in subjects with locally advanced high-risk cervical cancer (KEYNOTE-A18 / ENGOT-cx11 / GOG-3047). Sub-investigator for site 0542 (IRCCS National Cancer Institute Foundation) for external beam radiation therapy treatments and brachytherapy treatments.

- Phase III randomized clinical trial, double-blind, aimed at comparing chemoradiotherapy + Pembrolizumab (MK-3475) vs chemoradiotherapy in subjects with locally advanced high-risk cervical cancer (KEYNOTE-A18 / ENGOT-cx11 / GOG-3047). Sub-investigator for site 0539 (San Raffaele Hospital) for brachytherapy treatments.

- Phase III randomized clinical trial, double-blind, aimed at comparing Pembrolizumab vs adjuvant chemotherapy +/- radiotherapy in diagnoses of high-risk endometrial cancer after curative surgery (KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Sub-investigator for site 2122 (IRCCS National Cancer Institute Foundation) for external beam radiation therapy treatments and brachytherapy treatments.

-Phase III randomized clinical trial, double-blind, aimed at comparing Pembrolizumab vs adjuvant chemotherapy +/- radiotherapy in diagnoses of high-risk endometrial cancer after curative surgery (KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Sub-investigator for site 2130 (San Raffaele Hospital) for brachytherapy treatments.

-Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer